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Background 
Subclassification of ovarian carcinomas can be used to guide treatment and 
determine prognosis.  Germline and somatic mutations, loss of heterozygosity 
(LOH), and epigenetic events such as promoter hypermethylation can lead to 
decreased expression of BRCA1/2 in ovarian cancers.  The mechanism of 
BRCA1/2 loss is a potential method of subclassifying high grade serous 
carcinomas. 
Methods 
A consecutive series of 49 ovarian cancers was assessed for mutations status of 
BRCA1 and BRCA2, LOH at the BRCA1 and BRCA2 loci, methylation of the 
BRCA1 promoter, BRCA1, BRCA2, PTEN, and PIK3CA transcript levels, 
PIK3CA gene copy number, and BRCA1, p21, p53, and WT-1 
immunohistochemistry.   
Results 
Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 
mutations, or epigenetic loss of BRCA1.  All of these tumours were high-grade 
serous or undifferentiated type.  None of the endometrioid (n=5), clear cell (n=4), 
or low grade serous (n=2) carcinomas showed loss of BRCA1, whereas 47% of 
the 38 high-grade serous or undifferentiated carcinomas had loss of BRCA1.  It 
was possible to distinguish high grade serous carcinomas with BRCA1 mutations 
from those with epigenetic BRCA1 loss: tumours with BRCA1 mutations typically 
had decreased PTEN mRNA levels while those with epigenetic loss of BRCA1 
had copy number gain of PIK3CA.  Overexpression of p53 with loss of p21 
expression occurred significantly more frequently in high grade serous 
carcinomas with epigenetic loss of BRCA1, compared to high grade serous 
tumors without loss of BRCA1.  
Conclusions 
High grade serous carcinomas can be subclassified into three groups: BRCA1 
loss (genetic), BRCA1 loss (epigenetic), and no BRCA1 loss.  Tumors in these 
groups show distinct molecular alterations involving the PI3K/AKT and p53 
pathways.      
Background  
Ovarian cancer is the most fatal gynecological cancer in North American women 
and the fifth most common cause of cancer death.  Epithelial ovarian carcinomas 
(EOC) are subclassified according to tumor cell type and grade.  These different 
subtypes of ovarian cancer are associated with different molecular 
characteristics: high grade serous cancers typically contain TP53 mutations [1, 
2], low grade serous carcinomas often have RAS-RAF pathway activation and 
mutations in the KRAS and BRAF genes [3], low-grade endometrioid cancers are 
associated with mutations in the beta-catenin gene, CTNNB1 [4], and mucinous 
cancers frequently have mutations in KRAS [5].  Accurate subclassification of 
  
ovarian cancers is essential because different subtypes of ovarian cancer 
respond differently to treatment and have different prognoses [6].   
 
The majority of ovarian cancers are of serous subtype [7].  In a study of 220 
ovarian carcinomas, over half were categorized as serous and over 90% of these 
serous ovarian cancers were high grade (grade II or III) [8].  High grade serous 
ovarian cancers are associated with BRCA1 or BRCA2 mutations [9-11].  
BRCA1, located at 17q21 [12-14], and BRCA2, located at 13q12-q13 [15, 16] 
both encode tumor suppressors involved in repairing double-stranded DNA 
breaks and maintaining genomic stability [17-19]  Germline BRCA1 or BRCA2 
mutations are present in 10% to 15% of all EOCs [20, 21].  Less commonly, 
EOCs contain somatic mutations in these genes [22].  In addition, aberrant 
expression of BRCA1 or BRCA2 may occur through loss of heterozygosity or, in 
the case of BRCA1, promoter hypermethylation [23-27].  Unlike breast cancer, 
where patients with germline mutations in BRCA1 or BRCA2 have cancers that 
are distinct from sporadic breast cancers on the basis of morphology or gene 
profiling [28-30], ovarian cancers with germline BRCA1 or BRCA2 mutations are 
indistinguishable from their sporadic counterparts [11, 23, 31-33].  High grade 
serous ovarian cancers that have functional BRCA1 or BRCA2 are currently not 
separable from high grade serous cancers that have loss of function of these 
proteins, based on routine histopathological examination.  The challenge is to 
find methods to distinguish these subtypes of high grade serous cancers; this 
would stratify patients based on the underlying molecular events during 
oncogenesis, which is potentially highly relevant as these cancers may respond 
differently to treatment.  This has recently been demonstrated in vitro: inhibitors 
of poly(ADP-ribose) polymerase (PARP1) were found to be able to target and kill 
cells deficient in either BRCA1 or BRCA2 [34, 35].  PARP1 binds to single-
stranded DNA breaks, attracting proteins to repair DNA.  Inhibition of PARP1 
allows these single stranded breaks to progress to double stranded breaks 
through the resulting collapse of replication forks [34, 36].  The preferred double-
strand break repair mechanism is homologous recombination which relies on the 
activity of BRCA1 and BRCA2.  Thus, cells with loss of BRCA1 or BRCA2 
function that are treated with PARP1 inhibitors are unable to repair DNA breaks, 
which leads to crisis and cell death.   
 
We collected and analysed 49 consecutive ovarian tumor samples from 
consenting women diagnosed with invasive, non-mucinous EOC who were 
undergoing debulking surgery.  We pathologically characterized these samples 
and analysed them for BRCA1 and BRCA2 mutations, loss of heterozygosity at 
both loci, mRNA levels of BRCA1 and BRCA2, expression of BRCA1, and 
BRCA1 promoter hypermethylation.  In light of previous studies showing that 
promoter hypermethylation of BRCA2 is rarely if ever encountered in ovarian 
carcinoma [37-39], we did not undertake similar studies on the BRCA2 promoter.  
We then attempted to determine whether molecular profiles could be used to 
distinguish high grade serous cancers with BRCA1 mutations (germline or 
somatic), from high grade serous cancers with epigenetic loss of BRCA1 through 
 
promoter hypermethylation, and high grade serous cancers without BRCA1 loss.  
We focused on the PI3K/AKT and p53 pathways which play important roles in 
ovarian cancer [40-43].   
Methods 
Recruitment and tumor samples.  Between January 2004 and September 2005 
all women undergoing primary debulking surgery for ovarian carcinoma were 
invited to participate in this study at the Vancouver General Hospital and British 
Columbia Cancer Agency in Vancouver, Canada.  Women with mucinous and 
borderline tumors, and women who had received pre-operative chemotherapy 
were excluded.  Pathology was reviewed by a single pathologist (CBG).  Serous 
tumors were classified as low or high-grade as described previously [44]; all 
undifferentiated and clear cell carcinomas were considered high-grade.  
Endometrioid carcinomas were graded as grade 1, 2, or 3 according to the 
Silverberg grading system [45].  Ethical approval was obtained from the 
University of British Columbia Ethics Board (#H02-61375 and #H03-70606). 
 
DNA and RNA extraction.  Cancer tissue was split with part stored at -80 
degrees and the facing tissue fixed in formalin and placed in paraffin blocks.  
H&E sections were reviewed to ensure samples consisted of ≥ 70% tumor cells.  
DNA was extracted using the Puregene DNA Purification Kit (Gentra Systems, 
Inc, Wicklow, Ireland) according to manufacturer’s instructions from whole blood 
(germline analysis) or tumor samples (somatic analysis).  RNA was isolated with 
Trizol (Invitrogen, Carlsbad, CA) according to standard protocols. 
 
Loss of heterozygosity analysis.  Somatic loss of BRCA1/BRCA2 in tumor 
tissue was assessed for LOH using microsatellite markers for BRCA1 (D17S855 
(60°C), D17S1185 (58°C), D17S1323 (56°C), and D17S1325 (56°C)) [46], and 
BRCA2 (D13S260 (60°C), D13S171 (50°C), D13S267 (53°C), D13S217 (55°C)) 
[9].  PCR products were electrophoresed in an ABI Prism 3100 Genetic Analyzer 
(Applied Biosystems, Foster City, CA), and analyzed with Genescan v3.1 
software (Applied Biosystems, Foster City, CA).  LOH was defined as a complete 
or partial (≤ 50%) signal reduction of one allele in at least one marker.  
Microsatellite instability (MSI) was defined as the presence of novel alleles in the 
tumor DNA that were not present in normal DNA in at least one marker [47].   
 
dHPLC mutation screening and mutation analysis.  Screening for 
BRCA1/BRCA2 mutations was performed using denaturing high performance 
liquid chromatography (dHPLC).  Tumor DNA was mixed in a 3:1 ratio with 
corresponding germline DNA for all tumors shown to possess LOH to ensure that 
LOH did not mask somatic mutations [48].  For example, with intratumoral LOH, 
and mutation of the remaining allele, dHPLC screening would give a false 
negative result.  If the mutation is a germline mutation it will be picked up on 
dHPLC screening of germline DNA, however, a somatic mutation would be 
missed in both tumor and germline DNA without DNA mixing.  PCR primers and 
conditions were developed by the Royal Melbourne Hospital (Australia) and are 
 
available on request.  PCR primers were used to amplify each exon of BRCA1 
(24 exons) and BRCA2 (26 exons).  All exons with abnormal dHPLC profiles 
were PCR amplified and bi-directionally sequenced to identify mutations using 
ABI BigDye terminator v3.1 cycle sequencing kit (Applied Biosytems, Foster City, 
CA) and an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, 
CA). 
 
Multiplex Ligation-dependent Probe Amplification (MLPA) screening.  For 
the identification of germline BRCA1 single and multiple exon deletions or 
duplications, multiplex ligation-dependent probe amplification analysis (MLPA) 
kits SALSA P002 BRCA1 and SALSA P087 BRCA1 (MRC Holland, Amsterdam, 
NL) were used according to manufacturer directions.  A reduction or increase in 
RPA values to <0.7 or >1.3 was considered an indication of a deletion or a 
duplication, respectively [49]. 
 
BRCA1 and FANCF promoter hypermethylation analysis.  The BRCA1 
methylation status of each tumor was assessed using a technique similar to the 
MethyLight assay described previously [50].  Briefly, 500 ng of sample DNA was 
subjected to sodium bisulfite modification using the EZ DNA Methylation-Gold 
Kit, as recommended by the manufacturer (Zymo Research, Orange, CA).  After 
bisulfite treatment, DNA was amplified using real-time PCR with oligonucleotide 
primers complementary to a region of the MYOD1 promoter that did not contain 
any CpG dinucleotides but did contain non-CpG cytosines to ascertain the 
amount of converted input templates in each sample.  Hypermethylation of the 
BRCA1 promoter was then examined by real-time PCR amplification of bisulfite-
modified DNA using oligonucleotide primers specific for a fully methylated 
bisulfite-converted portion of BRCA1 promoter such that only CpG islands that 
were methylated at every CpG dinucleotide interrogated by the primers and 
probes would be amplified and generate fluorescent signal.  The sequences of 
the primers used to amplify and detect methylated BRCA1 promoter region were 
5'-TAGAGTTTCGAGAGACGTTTGGTTT-3' (forward primer) and 5'-
CGCTTTTCCGTTACCACGA-3' (reverse primer).  The primers for MYOD1 were 
5’-CCA ACTCCA AATCCCCTC TCTAT-3’ (forward primer) and 5’-
TGATTAATTTAGATTGGGTTTAGAGAAGGA-3’ (reverse primer).  The amount 
of methylated DNA (PMR, percentage of methylated reference) [51] at the 
BRCA1 locus was calculated by dividing the BRCA1: MYOD1 ratio of a sample 
by the BRCA1: MYOD1 ratio of CpG methylated Jurkat genomic DNA (New 
England Biolabs, Ipswich, MA) and multiplying by 100.  Reactions using CpG 
methylated Jurkat genomic DNA were used to normalize for any difference in 
amplification efficiencies between BRCA1 and MYOD1.  The PMR serves as an 
index of the percentage of bisulfite converted input copies of DNA that are fully 
methylated at the primer hybridization sites.  The PMR values obtained by 
MethyLight were dichotomized at 4 PMR for statistical purposes as described 
previously [51].  Samples containing 4 PMR or higher were designated as 
methylated, whereas samples containing less than 4 PMR were designated as 
unmethylated.  It is important to note, however, that the PMR may be >1 if copies 
 
of MYOD1 are deleted relative to the gene of interest, or copies of the gene of 
interest are gained relative to MYOD1 in any given sample.  PCR experiments 
were carried out in a volume of 10 µL with 384-well plates and an Applied 
Biosystems 7900HT Sequence Detector (Applied Biosystems, Foster City, CA).  
The fluorescence signal of the quantitative methylation-specific PCR was 
generated by SYBR Green I.  Samples (10ng bisulfite-treated DNA) were run in 
triplicate containing 5 µL SYBR Green Master Mix (Applied Biosystems, Foster 
City, CA) and 5 pmol of each forward and reverse primer.  Bisulfite-converted 
CpG methylated Jurkat Genomic DNA (New England Biolabs, Ipswich, MA) 
served as a positive control and was used to generate a standard curve to 
quantify the amount of fully methylated promoters in each reaction.  PCR 
amplification was done by means of the following procedure: 95ºC for 15 
minutes, followed by 40 cycles at 95ºC for 15 seconds, 62ºC for 1 minute.  A 
subsequent dissociation curve analysis checked the specificity of products.  
FANCF promoter hypermethylation was assessed using a HpaII digest assay 
and methylation-specific PCR protocol previously reported by Taniguchi et al 
[52].  
 
Real-time Q-RT-PCR.  Extracted RNA was treated with DNAse I (Invitrogen, 
Carlsbad, CA) prior to creating cDNA using random hexamer priming and MMLV 
reverse transcriptase (Invitrogen, Carlsbad, CA).  Applied Biosystems Taqman 
primer/probe kits (Hs00173233_m1 (BRCA1), Hs00609060_m1 (BRCA2),  
Hs01920652_s1 (PTEN), Hs00907966_m1(PIK3CA)) were used to quantify 
mRNA expression levels using real-time qRT-PCR [37] and an ABI Prism 
7900HT Sequence Detection System (Applied Biosystems, Foster City, CA).  
Relative gene expression quantification was calculated according to the 
comparative Ct method using human 18S ribosomal RNA (Applied Biosystems, 
Foster City, CA) and commercial RNA controls (Stratagene, La Jolla, CA).  
Relative quantification was determined as follows: 2 –(∆Ct sample – ∆Ct calibrator).  Ratios 
(tumor relative gene expression:average of all tumors) less than 0.7 or greater 
that 1.3 for were scored as decreased or increased mRNA expression, 
respectively. 
 
Immunohistochemistry.  The BRCA1 antibody Ab-1 (Oncogene, 1:50 dilution) 
was used and antigen retrieval was performed in 1x EDTA buffer (pH 8.0) by 
microwaving for 2 minutes, and then boiling in a waterbath for 30 minutes.  
Endogenous peroxide activity was blocked with 3% hydrogen peroxide and then 
sections were incubated with 2.5% normal horse blocking serum.  Following 
incubation with the primary antibody, the Vector Laboratories (Burlingame, CA) 
ImmPRESS kit was used according to the manufacturer’s recommendations to 
visualize antibody complexes.  Nuclear staining was assessed by CBG, who was 
blinded to all other BRCA analysis.  Tumors were considered BRCA1 positive if 
greater than 1% of tumor nuclei showed staining.  IHC was also performed with 
the following panel of previously validated antibodies using a Ventana (Tucson, 
AZ) automated immunostainer: p21 (Neomarkers, Fremont , CA, clone DCS-
60.2, 1:100 dilution), p53 (Dako, Carpinteria, CA, clone DO-7, 1:400 dilution), 
 
and WT-1 (Dako, Carpinteria, CA, clone 6F-H2, 1:50 dilution).  BRCA1 IHC was 
done on whole sections, while other IHC markers were assessed using sections 
from a tissue microarray constructed with two 0.6 mm cores per case. 
 
Molecular Inversion Probe (MIP) Copy Number 
The MIP copy number assay was done as described previously [53] with some 
modifications.  Specifically, the current protocol is a modification of the Targeted 
Genotyping protocol commercialized by Affymetrix [54].  Test DNA samples were 
diluted to16 ng/µl.  Molecular inversion probes were annealed to DNA by mixing 
4.7 µl of DNA (75 ng total), 0.75 µl of Buffer A, 1.1 µl of the 53K molecular 
inversion probe pool (200 amol/ µl/probe) and 0.045 µl of Enzyme A in a 384-well 
plate on ice.  The reaction was incubated for 4 min at 20○C, 5 min at 95○C, then 
overnight at 58○C.  Following annealing, 13 µl of Buffer A and 1.25 µl of Gap Fill 
Enzyme mix were added to each reaction and 9 µl of reaction volume was 
transferred to each of two wells in a 96-well plate.  Molecular inversion probes 
were circularized with 4 µl of dNTP mix at 58○C for 10 min.  Linear probes and 
genomic DNA were eliminated by addition of 4 µl of Exo Mix and incubation at 
37○C for 15 min, followed by universal primer amplification for 18 cycles (20 sec 
at 95○C, 40 sec at 64○C, and 10 sec at 72○C).  For labelling reactions, the 
product was further amplified for 10 cycles using labelled primers, then subjected 
to cleavage by HY Digest Mix at 37○C for 2 hours.  The cleaved MIP products 
were mixed with Hybridization Cocktail, denatured, and hybridized to 70K 
Universal Taq arrays at 39○C for 16 h (two arrays per sample).  The overnight 
hybridized arrays were washed on a GeneChip® Fluidics Station FS450 and 
stained by SAPE at 5ng/ml (Invitrogen).   
 
Copy number estimation was obtained from the hybridization signals as 
previously described [55], with the following modifications: the color-separation 
step was omitted as the single color readout on two arrays prevented the spectral 
overlap that occurs with multi-color readouts, and Langmuir correction was 
performed instead of linear calibration of allele signals [56].  Copy numbers over 
3.0 were considered amplification events and copy numbers below 1.5 were 
considered deletion events.  
  
Data analysis.  Epigenetic BRCA1 loss was defined as having promoter 
hypermethylation accompanied by either low relative BRCA1 mRNA expression, 
negative BRCA1 IHC, or both low BRCA1 mRNA and negative BRCA1 IHC.  
Tumors without promoter hypermethylation and with positive BRCA1 IHC were 
not considered to have BRCA1 loss.  Tumors with negative BRCA1 IHC without 
promoter hypermethylation were considered equivocal for BRCA1 loss.  A chi-
squared test or Fisher exact test was used to analyze categorical variables (MIP 
copy number, IHC) and a student’s t-test was used to analyze continuous 
variables (RNA expression).  
 
Results  
Representative results of analysis for BRCA1 mutations, BRCA1 loss of 
heterozygosity, and BRCA1 promoter hypermethylation are shown in Figure 1.  
 
BRCA1 findings for all tumors are presented as Figure 2.  Based on these 
results, ovarian cancers were divided into six groups: (1) BRCA1 mutations, (2) 
BRCA1 epigenetic loss, (3) equivocal for BRCA1 loss, (4) high grade 
serous/undifferentiated cancers without BRCA1 loss, (5) BRCA2 mutations, and 
(6) clear cell, endometrioid, and low grade serous cancers.   
 
Nine of the samples (18%) carried BRCA1 mutations (eight germline, one 
somatic) and three samples (6%) had BRCA2 mutations (two germline, one 
somatic).  No intragenic deletions in BRCA1 were detected by MLPA analysis.  
Nine samples (18%) were found to have loss of BRCA1 due to epigenetic events; 
these samples all had hypermethylation of the BRCA1 promoter accompanied by 
decreased BRCA1 mRNA levels (relative qRT-PCR expression <0.7) and/or lack 
(less than 1% of tumour nuclei) of BRCA1 immunohistochemical staining.  Five 
samples (10%), which did not carry BRCA1 mutations, were all unmethylated at 
the BRCA1 promoter; these were classified as “equivocal for BRCA1 loss” 
because they fulfilled two of the following criteria: loss of heterozygosity (LOH) at 
the BRCA1 locus, decreased BRCA1 mRNA levels, or lack of BRCA1 
immunohistochemical staining.  All samples (n=26) with BRCA1 or BRCA2 
mutations, epigenetic loss of BRCA1, or classified as equivocal for BRCA1 loss 
were of high grade serous/undifferentiated type.  Twelve tumors (24%) of high 
grade serous/undifferentiated type did not have BRCA1 mutations or epigenetic 
loss, or BRCA2 mutations.  Thus, considering only the 38 high grade 
serous/undifferentiated tumours in our study, 18 (18/38, 47%) had loss of BRCA1 
either through genetic or epigenetic events, three (3/38, 8%) carried germline or 
somatic BRCA2 mutations, 12 (12/38, 32%) had preservation of BRCA1 
expression and no mutations in BRCA1 or BRCA2, and the remaining five tumors 
(5/38, 13%) were equivocal for BRCA1 loss and did not have BRCA2 mutations.  
FANCF promoter hypermethylation was not observed in any of these cases.     
 
The remaining 11 tumour samples (22%) (i.e. those cases other that the high 
grade serous/undifferentiated carcinomas) were either clear cell (4), 
endometrioid (5), or low grade serous type (2).  These samples were all negative 
for BRCA1 or BRCA2 mutations, negative for BRCA1 promoter 
hypermethylation, and positive for BRCA1 expression as determined by 
immunohistochemistry.   
 
We further analyzed the 35 high grade serous/undifferentiated tumour samples 
that did not contain BRCA2 mutations using a combination of MIP copy number, 
qRT-PCR, and immunohistochemistry in order to determine whether these 
different groups could be classified according to specific molecular features other 
than BRCA1 or BRCA2 abnormalities (Figure 3).  The number of tumors with 
BRCA2 mutations (n=3) was considered too small for meaningful further analysis 
 
of this subset and was therefore excluded.  Thirty-one of these tumours were 
positive for WT1 expression by immunohistochemistry, a marker of serous cell 
type in EOC, thus confirming our histopathological subclassification [57]; all clear 
cell and endometrioid cancers in this study were negative for WT1 expression 
(data not shown).  Currently, the group of high grade serous/undifferentiated 
carcinoma is indivisible based on morphology or routinely used diagnostic 
molecular markers.  We specifically focused on the PI3K/AKT and p53 pathways 
which are known to be important in EOC.  We found that those tumours with 
BRCA1 loss through genetic events differed according to several parameters 
from tumours with loss of BRCA1 due to epigenetic events.  Most striking were 
differences in PIK3CA copy number as determined by the MIP copy number 
assay.  While none of the BRCA1 mutation positive cases demonstrated an 
increased PIK3CA copy number almost all (7/8) of the samples with epigenetic 
loss of BRCA1 had increased copy number at the PIK3CA locus.  The PIK3CA 
copy number increases were low level (mean amplification ratio 2.7, range 1.7-
4.9), and in all but one case amplification of PIK3CA was associated with 
amplification of the entire chromosomal arm.  PIK3CA mRNA levels were 
assessed using qRT-PCR and relative mRNA levels were found to correlate with 
copy number ratios (p=0.02).  Specificity of MIP copy number data was verified 
by assessing c-myc amplification; while PIK3CA copy number appeared to be 
selectively increased in specific subgroups, amplification at the c-myc locus was 
observed at similar frequencies in all subgroups.  Interestingly, decreased PTEN 
mRNA levels observed in cancers with BRCA1 mutations and increased PI3KCA 
copy number in cancers with epigenetic loss of BRCA1 were almost mutually 
exclusive (Figure 4).  These events represent two separate mechanisms of 
activation of the canonical PI3K/AKT pathway.   
 
We further compared those tumors with either genetic or epigenetic loss of 
BRCA1 with high grade serous cancers without evidence of BRCA1 loss (Table 
1).  Representative immunohistochemical images for BRCA1, p53, and p21 from 
all three of these groups are shown in Figure 5.  MIP copy number analysis of the 
nine tumours that had BRCA1 mutations showed that there was no loss or gain 
at the region of chromosome 3 that contains the gene for PIK3CA and only four 
(44%) samples stained positively for p53.  By contrast, of the samples that had 
loss of BRCA1 due to epigenetic events, seven of eight samples (88%) had an 
increased PIK3CA copy number, and eight of nine samples (89%) stained 
positively for p53.  In addition, high grade serous cancers without BRCA1 loss 
had low frequencies of positive p53 staining (4/12, 33%) and increased PIK3CA 
copy number (3/12, 25%), similar to cancers with BRCA1 mutations but distinct 
from cancers with epigenetic loss of BRCA1.  In two cases (#366 and #217) we 
were unable to obtain MIP copy number data.  It was noted that positive p53 
staining was most often accompanied by negative p21 staining.  The expression 
of p21 is increased in response to p53.  High level overexpression of p53 
correlates with p53 mutations and loss of function and would be anticipated to be 
associated with decreased p21 expression, as we observed.  This p53+/p21- 
 
immunophenotype was significantly more common in tumors with BRCA1 
epigenetic loss than in tumors without BRCA1 loss (Table 1).   
Discussion  
The sub-classification of ovarian carcinomas, which is based on histopathological 
subtype and grade, is unable to adequately predict prognosis or response to 
treatment.  Administration of adjuvant platinum/taxane chemotherapy is the 
standard treatment for ovarian carcinoma following debulking surgery [58].  
Approximately 70% of advanced-stage ovarian carcinomas, however, will recur 
with development, ultimately of platinum-resistant disease [59].  A comparison of 
clinical outcomes between ovarian cancer patients with BRCA1 promoter 
hypermethylation to patients with BRCA1 mutations and wild-type BRCA1 genes 
demonstrated that patients with BRCA1 promoter hypermethylation had 
significantly shorter survival times compared to the other two groups [60].  
Ovarian carcinomas in patients with BRCA1, in contrast are associated with a 
favourable prognosis [23, 61].  This data suggests that different abnormalities in 
BRCA1 could be associated with different clinical outcomes and possibly distinct 
alterations in other underlying molecular abnormalities.  For example, the colon 
cancers from patients with inherited mutations in DNA mismatch repair genes 
differ from sporadic cancers with microsatellite instability due to hypermethylation 
of the MLH1 promoters [62], with respect to age of onset of disease, pathology, 
and molecular alterations [63].  
 
 
We evaluated 49 ovarian carcinomas and categorized them according to 
pathology and BRCA1 and BRCA2 status.  We further evaluated 35 high grade 
serous/undifferentiated tumours that we divided into four groups based on 
BRCA1 mutation status, expression, and promoter hypermethylation.  We 
observed increased positive p53 immunohistochemical staining, which correlated 
with negative p21 immunostaining, in cancers with epigenetic BRCA1 loss, 
compared to cancers with BRCA1 mutations and high grade 
serous/undifferentiated cancers without BRCA1 loss.  p53 is a tumor suppressor 
that is involved in the progression of many cancers and is the most commonly 
mutated gene in ovarian carcinomas [37].  Typically, mutations in p53 result in 
accumulation of p53 in the nucleus and the majority of cases with abundant p53 
detectable by immunohistochemistry are p53 mutant [64, 65].  The p53 protein is 
an important mediator of apoptosis resulting from DNA damage, stress, or 
chemotherapy [66].  p21 is a downstream effector of the cell cycle arrest function 
of p53 and is upregulated at the transcriptional level by wildtype but not mutated 
p53 [67].  At present, p53 mutation status or expression is not used to guide 
clinical decisions [68].  We have observed that p53 overexpression correlates, as 
expected, with loss of p21 expression.  Furthermore the phenotype of p53 
overexpression with loss of p21 is significantly more common is high grade 
serous/undifferentiated tumors with epigenetic loss of BRCA1 compared to high 
grade serous/undifferentiated tumors without loss of BRCA1. 
 
 
In addition, we found that ovarian carcinomas with loss of BRCA1 through 
genetic events and those with BRCA1 loss through epigenetic events both have 
activation of the PI3K/AKT pathway, though the mechanism of activation is 
different.  PI3K phosphorylates phosphatidylinositol lipids in response to 
activation by receptor tyrosine kinases [69].  Its activity has been linked to 
proliferation, differentiation, cell adhesion, apoptosis, tumorigenesis, and 
angiogenesis [70].  PTEN is a phosphatase whose activity counters PI3K.  The 
serine/threonine kinase AKT is a downstream target of PI3K [71] and the activity 
of one of its isoforms, AKT1, is elevated in ovarian carcinomas [72].  Both 
decreased PTEN levels and amplification of PIK3CA lead to increased 
phosphorylation of AKT and it has been previously shown that ovarian cancers 
often have alterations in PI3K and PTEN [73-75].  This is the first study, however, 
to report that decreased PTEN expression levels are associated with ovarian 
carcinomas carrying BRCA1 mutations while increased PI3KCA copy number is 
associated with ovarian carcinomas with epigenetic loss of BRCA1.  It has been 
previously demonstrated in breast cancer and glioblastoma that PIK3CA 
mutations and PTEN loss are virtually mutually exclusive, suggesting that 
abrogation of just one of these proteins is sufficient for tumorigenesis [76,77].  
We observe a similar result in our ovarian serous cancer samples; it  is likely that 
deregulation of this pathway, while critical for tumorigenesis, can be 
accomplished through alteration of a single key molecule at which point selective 
pressure is relieved for altering other proteins involved in this signalling pathway.  
Our findings in serous ovarian carcinoma, and the previous results from studies 
of breast cancer and glioblastoma, are in contrast to ovarian carcinoma of 
endometrioid type [78], and endometrial cancer [79,80], where PTEN mutations 
and PIK3CA mutations frequently co-exist.  This is yet another example of 
molecular events during the genesis of ovarian cancer that show tumor cell type 
specificity, and reinforces the need to consider cell type differences in studies of 
ovarian cancer pathogenesis.     
 
We would expect that cancers with activation of the PI3K/AKT pathway may not 
respond well to  common chemotherapy, as overexpression of activated AKT 
decreases apoptosis induced by paclitaxel in ovarian cancer cells [81] and 
introduction of the catalytic subunit of PI3K into ovarian cancer cells causes 
resistance to paclitaxel [82].  In addition, the PI3K inhibitor, LY294002, has been 
shown to decrease growth of ovarian carcinoma and ascites formation in mouse 
xenograft models of ovarian carcinoma [83].  As therapies continue to be 
developed that target the PI3K/AKT pathway, it will be essential to understand 
the molecular alterations that are affecting this pathway in different types of 
ovarian carcinomas.     
 
The need for meaningful sub-classification of ovarian carcinoma is critical for 
improving the treatment and prognosis of patients.  Though sub-classification 
may be done based on BRCA1 genetic testing, this cannot be done in a timely 
fashion such that it could be used to guide therapy of patients newly diagnosed 
with ovarian cancer.  This is extremely important as patients must embark on 
  
therapy shortly after diagnosis.  In addition, as new therapeutics are developed, 
rapid identification of appropriate patients will be necessary for clinical trials.  Our 
results demonstrate that it may be possible to categorize patients based on rapid 
molecular tests to identify patients who are likely to harbour BRCA1 mutations.  
Negative BRCA1 immunohistochemical staining, decreased BRCA1 mRNA, lack 
of PI3K amplification, and absence of BRCA1 promoter hypermethylation is an 
example of a molecular profile that could be used to identify these patients.  This 
would also allow more cost effective and efficient mutation screening in patients 
presenting with ovarian carcinoma.  
Conclusions  
This is the first study to comprehensively examine data from detailed analysis of 
BRCA1 and BRCA2 abnormalities in ovarian cancer.  Results presented here 
demonstrate that high grade serous/undifferentiated carcinomas can be 
subclassified based on the underlying BRCA abnormalities.  Such clinically 
relevant subclassification is critical for developing specific treatements for ovarian 
cancer patients which will lead to improved prognosis and management of 
disease. 
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Figures 
Figure 1: Assessment of BRCA1 loss  (A) Mutation screening showing the 
abnormal denaturing high performance liquid chromatography profile 
corresponding to the 1351delAT mutation in tumor 223.  The single blue line 
represents the electropherogram from a normal control, while the purple line 
represents the abnormal profile formed by the mutated exon 11c in tumor 223.  
(B) Direct DNA sequencing demonstrating the 185delAG mutation in tumor 283.   
Only the mutant allele is seen in the tumor because LOH is present.  (C-E) Loss 
of heterozygosity (LOH) analysis using BRCA1-associated microsatellite markers 
visualized on an ABI Prism 3100 Genetic Analyzer, where LOH is defined as 
 
>50% decrease in area under the curve when germline DNA (upper tracing) and 
tumor DNA (lower tracing) are compared.  (C) The lack of LOH in tumor 240 
demonstrated using microsatellite marker D17S1185, (D) LOH in tumor 283 
demonstrated using microsatellite marker D17S855.  (E) Microsatellite instability 
demonstrated in tumor 156 using microsatellite marker D17S1185.  (F, G, H, and 
I) Methylation analysis of BRCA1 gene using fluorescence-based, quantitative, 
real-time PCR (TaqMan) using SYBR Green 1 as detection method.  Two sets of 
primers, designed specifically for bisulfite converted DNA, were used: a 
methylated set for the BRCA1 gene and a reference set (MYOD1) to control for 
input DNA.  Specificity of the reactions for methylated DNA were confirmed 
separately using human genomic DNA (unmethyated; F) and CpG methylated 
Jurkat genomic DNA (methylated; G), respectively.  H and I show representative 
examples of results from assessment of BRCA1 loss through promoter 
hypermethyation.  Tumor 178 shows only unmethylated BRCA1 promoter, while 
tumor 345 shows evidence of BRCA1 promoter hypermethylation.   
 
Figure 2:  Summary of BRCA1 abnormalities and associated features:  
Pathology refers to the tumor histopathology.  Serous or Ser = serous 
carcinoma; Undiff = undifferentiated carcinoma; HG = high-grade; LG = low-
grade; Clear cell = clear cell carcinoma; Endo = endometrioid carcinoma; G1 = 
grade 1; G2 = grade 2; G3 = grade 3.  BRCA1 Status:  Mut = mutation; G = 
germline; S = somatic; N = no mutations.  LOH = loss of heterozygosity where 
LOH indicates that loss of heterozygosity is present, NO indicates that loss of 
heterozygosity is not present, and MSI indicates that microsatellite instability is 
present in the tumor.  Meth refers to BRCA1 promoter hypermethylation.  Tumors 
containing ≥ 4% fully methylated molecules are designated as methylated (M) 
and are highlighted in orange, whereas tumors containing < 4% are designated 
as unmethylated (U).  RNA refers to relative RNA expression compared to the 
average RNA expression in all samples, where the average RNA expression = 
1.0.  Tumors with relative RNA expression <0.7 are highlighted in aqua as 
showing BRCA1/BRCA2 loss.  IHC refers to BRCA1 immunohistochemistry; (+) 
indicates tumors with > 1% of nuclei stained positive for BRCA1, (−) indicates 
tumors with <1% of nuclei positive.  N/A indicates that the data is not available for 
technical reasons. 
 
Figure 3: Summary of analysis of high grade (HG) serous/undifferentiated 
ovarian tumors:  MIP copy number results are shown for c-myc and PIK3CA 
loci.  MIP copy number values over 3.0 are highlighted and correspond to 
amplification.  Relative mRNA levels for PIK3CA and PTEN were assessed using 
qRT-PCR; levels over 1.3 (highlighted in green) are considered elevated and 
levels below 0.7 (highlighted in aqua) indicate decreased transcript levels.   
Associated immunohistochemical markers p21, p53, and WT-1 refer to 
immunohistochemical staining results.  Scoring of immunostaining was done as 
follows: p21: 0 = <5% nuclei positive and 1 = >5% of nuclei positive.  p53: 0 = 
<50% nuclei positive and 1 = >50% of nuclei positive.  WT1: 0 = <5% nuclei 
  
positive, 1 = 5-50% nuclei positive, and 2 = >50% nuclei positive.  N/A indicates 
that the data is not available for technical reasons. 
 
Figure 4: Correlation between decreased PTEN mRNA levels and 
amplification at the PIK3CA locus:  Relative PTEN mRNA levels as 
determined by qRT-PCR are plotted along the X-axis and PIK3CA MIP copy 
number results are plotted along the Y-axis for high grade serous ovarian tumors 
with BRCA1 mutations (open circles) and high grade serous ovarian tumors with 
epigenetic loss of BRCA1 (filled triangles).  MIP copy number values over 3.0 
indicate amplification.   
 
Figure 5: Immunohistochemistry results: Representative 
immunohistochemistry results for high grade serous ovarian tumors with BRCA1 
mutations (tumor #327, top row), with epigenetic loss of BRCA1 (tumor #332, 
middle row), and without loss of BRCA1 (tumor #372, bottom row).  
Immunohistochemical staining is shown for BRCA1 (left column), p53 (middle 
column) and p21 (right column).    
  
 Tables 
Table 1: Comparison of PIK3 CA amplification or p53/p21 protein expression in 
High Grade Serous Ovarian Tumours 
p53/p21 IHC Group PIK3CA amplification (MIP copy number)  +/- +/+, -/- -/+ 
BRCA1 loss through  
mutation 0/9
*+ 4/9 2/9 3/9 
BRCA1 epigenetic loss 7/8*+ 8/9** 1/9 0/9 
No BRCA1 loss 3/11+ 3/12** 5/12 4/12 
* p = 0.02 for pairwise comparison based on Bonferroni-Holmes corrected Fisher exact test 
** p = 0.03 for pairwise comparison based on Bonferroni-Holmes corrected Fisher exact test 
+ p = 0.001 for threeway comparison based on Bonferroni-Holmes corrected Fisher exact test 
 
 
 
 
 
  
Human genomic DNA
MYOD1
BRCA1
MYOD1
BRCA1
CpG methylated Jurkat
genomic DNA
(F) (G)
MYOD1
BRCA1
345178
MYOD1
BRCA1
(H) (I)
BRCA1 status
Mut LOH Meth RNA IHC
186 Ser/Undiff-HG G NO U 0.44 –
223 Serous - HG G MSI U 0.14 –
329 Serous - HG G LOH U 0.02 –
293 Serous - HG G LOH U 0.65 –
283 Serous - HG G LOH U 3.1 –
239 Serous - HG G LOH U 0.16 –
336 Ser/Undiff-HG G LOH U 0.1 –
327 Serous - HG G LOH U 0.04 –
379 Serous - HG S LOH U 0.07 –
217 Serous - HG N LOH M 0.08 –
330 Serous - HG N LOH M 0.07 –
332 Serous - HG N LOH M 0.08 –
388 Serous - HG N LOH M 0.67 –
363 Serous - HG N LOH M 0.27 –
161 Ser/Undiff-HG N LOH M 0.09 –
344 Serous - HG N LOH/MSI M 0.3 –
345 Serous - HG N MSI M 0.41   +
384 Serous - HG N LOH M 0.15 –
201 Ser/Undiff-HG N LOH U 1.87 –
178 Serous - HG N LOH U 0.42 –
229 Serous - HG N LOH N/A 0.19 –
309 Serous - HG N NO U 0.56 –
394 Serous - HG N LOH U 0.89 –
195 Serous - HG N N.A. U 1.53   +
236 Serous - HG N LOH U 1.69   +
280 Ser/Undiff-HG N LOH U 3.11   +
172 Serous - HG N LOH U 2.21   +
254 Serous - HG N LOH U 0.48   +
319 Serous - HG N LOH U 0.62   +
372 Serous - HG N LOH U 2.02   +
208 Undiff - HG N LOH U 0.81   +
273 Undiff - HG N LOH U 1.54   +
240 Undiff - HG N NO U 0.41   +
297 Serous - HG N NO U 1.766   +
366 Serous - HG N LOH U 2.25   +
163 Serous - HG N LOH U 2.08   +
305 Serous - HG N LOH U 1.54 –
212 Serous - HG N LOH U 1.22   +
198 Clear cell N NO U 1.55   +
213 Clear cell N NO U 2.9   +
219 Clear cell N NO U 0.58   +
392 Clear cell N NO U 1.51   +
242 Endo - G2 N NO U 1.02   +
281 Endo - G2 N NO U 1.35   +
334 Endo - G1 N NO U 1.18   +
156 Endo - G2 N MSI U 1.42   +
343 Endo - G2 N NO U 0.27   +
221 Serous - LG N LOH U 1.46   +
324 Serous - LG N NO U 0.5   +
clear cell, 
endometriod, 
and low grade 
serous        (No 
BRCA1 loss)
High grade 
carcinoma 
with epigenetic 
BRCA1 loss
Equivocal 
BRCA1 loss
High grade 
carcinoma 
without BRCA1 
loss
BRCA2 loss 
through 
mutation
# Pathology Classification
BRCA1 loss 
through 
germline or 
somatic 
mutation
C-MYC PIK3CA PIK3CA PTEN p53 p21 WT1
186 Ser/Undiff-HG 2.4 2.7 1.68 0.58 0 0 2
223 Serous - HG 5.8 2.5 0.48 0.32 1 0 2
329 Serous - HG 3.4 2.0 0.1 0.11 1 0 2
293 Serous - HG 2.6 2.4 1.05 0.94 0 1 2
283 Serous - HG 3.3 2.0 0.62 0.55 1 0 2
239 Serous - HG 3.0 2.3 0.33 0.45 0 0 0
336 Ser/Undiff-HG 9.6 1.7 0.12 0.06 0 1 0
327 Serous - HG 2.0 2.4 0.07 0.1 1 0 2
379 Serous - HG 3.6 2.0 0.68 0.33 0 1 2
217 Serous - HG NA NA 1.18 1.14 1 0 2
330 Serous - HG 2.9 3.2 0.42 0.52 1 0 2
332 Serous - HG 5.1 4.9 2.08 0.99 1 0 2
388 Serous - HG 3.2 2.9 1.12 0.67 1 0 2
363 Serous - HG 5.0 3.6 3.31 1.37 0 0 2
161 Ser/Undiff-HG 2.5 3.0 1.02 0.39 1 0 2
344 Serous - HG 3.0 3.3 1.6 0.89 1 0 2
345 Serous - HG 5.8 3.9 2.02 0.39 1 0 2
384 Serous - HG 3.8 3.2 2.53 2.69 1 0 2
201 Ser/Undiff-HG 2.7 2.9 0.75 2.65 1 0 2
178 Serous - HG 5.7 2.8 2.64 0.75 1 0 2
229 Serous - HG 4.2 3.1 0.29 0.32 1 0 2
309 Serous - HG 1.9 2.2 1.18 2.2 0 0 2
394 Serous - HG 2.4 2.2 1.05 0.72 0 0 2
195 Serous - HG 3.9 2.1 1.09 2.71 1 0 2
236 Serous - HG 3.3 2.7 1.22 0.94 0 0 2
280 Ser/Undiff-HG 7.7 3.1 2.18 0.66 1 1 2
172 Serous - HG 2.1 1.8 0.86 0.74 0 1 0
254 Serous - HG 2.9 2.0 0.38 0.58 0 0 2
319 Serous - HG 3.2 1.9 0.4 0.75 0 1 2
372 Serous - HG 4.0 3.6 2.89 1.36 0 1 1
208 Undiff - HG 4.9 3.7 1.03 1.06 0 0 2
273 Undiff - HG 3.9 1.9 0.33 0.39 1 0 1
240 Undiff - HG 2.8 2.2 0.36 0.47 0 1 0
297 Serous - HG 2.0 2.2 2.06 3.14 0 0 2
366 Serous - HG NA NA 0.83 0.66 1 0 2
MIP COPY NUMBER
# Pathology
qRT-PCR IHC
High grade 
carcinoma 
without BRCA1 
loss
Classification
BRCA1 loss 
through germline 
or somatic 
mutation
High grade 
carcinoma with 
epigenetic BRCA1 
loss
Equivocal BRCA1 
loss


